Elinogrel (INN USAN) was an experimental antiplatelet drug acting as a P2Y12 inhibitor. Similarly to ticagrelor and in contrast to clopidogrel elinogrel was a reversible inhibitor that acted fast and short (for about 12 hours) and it was not a prodrug but pharmacologically active itself. The substance was used in form of its potassium salt intravenously for acute treatment and orally for long-term treatment. Development was terminated in 2012.
This page contains content from the copyrighted Wikipedia article "Elinogrel"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
